CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向 TM4SF1 的 CAR-T 细胞构建及其在卵巢癌中的抗肿瘤能力
英文原题：Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer.
查看英文原题
Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
卵巢癌（OC）是致死率最高的妇科恶性肿瘤，平均5年生存率为49.1%。临床实践中，减瘤术和化疗仍是晚期OC的常规治疗。然而，总体预后仍不佳，迫切需要肿瘤医师开发新疗法。作为免疫疗法的一个分支，嵌合抗原受体（CAR）T细胞疗法已成功治疗血液系统恶性肿瘤。TM4SF1是多种肿瘤中的潜在生物标志物，已证实在卵巢癌中高表达。本研究构建了第三代靶向TM4SF1的CAR-T 细胞药物治疗卵巢癌。CAR-T 细胞在体外对TM4SF1阳性肿瘤细胞系表现出特异性细胞毒性，并在体内抑制SKOV3来源肿瘤生长。这是首次报告靶向TM4SF1的CAR-T 疗法用于卵巢癌。结果提示TM4SF1可能是治愈OC的极有前景靶点，并显示TM4SF1靶向免疫疗法的潜力。
展开英文摘要原文
Ovarian cancer (OC) is the most lethal gynecological malignancy with a 5-year survival rate of 49. 1% on average. In clinical practice, cytoreduction and chemotherapy remain the conventional treatment for advanced OC.
However, the overall prognosis remains poor, which urges oncologists to develop new treatments. Chimeric antigen receptor (CAR)-T therapy as a branch of immunotherapy had gained a success in treating hematological malignancies. TM4SF1, a potential biomarker in many tumors, was validated highly expressed in ovarian cancer.
Here we constructed a 3 rd generation CAR-T agent targeting TM4SF1 to treat ovarian cancer. CAR-T cells showed a specific cytotoxicity against TM4SF1 positive tumor cell lines in vitro and repressed SKOV3-derived tumor growth in vivo. This is the first time reporting a CAR-T therapy targeting TM4SF1 in ovarian cancer.
Our results suggested that TM4SF1 could be a very promising target in curing OC and showed the possibility of TM4SF1-based immunotherapy.
论文信息
- 作者
- Shen Y、Liu G、Zhang Q、Tian X、Ouyang L、Zhang L
- 第一作者单位
- State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China.China
- 通讯作者单位
- State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China. Electronic address: ouyanglm@ecust.edu.cn.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Immunology letters2023 Mar
- 原文标识
- PubMed 36739093 · DOI 10.1016/j.imlet.2023.01.011